constitutive oncogenic signaling
/ oncogene = ONK-o-jeen; constitutive = kon-STIT-yoo-tiv /
Every signaling switch we have met is supposed to flip on when a signal arrives and flip off when it leaves. Cancer is, at its molecular heart, signaling switches that get stuck on. Constitutive means always on, regardless of input — and an oncogene is a gene whose protein, when mutated to be constitutively active, drives a cell toward cancer. Picture a doorbell that keeps ringing even with no one at the door: the cell keeps hearing grow and divide when nothing outside is actually telling it to.
Healthy growth-signaling genes are called proto-oncogenes — perfectly normal genes for receptors, GTPases, and kinases that promote division when properly triggered. A mutation turns a proto-oncogene into an oncogene by jamming its product permanently on. The damage can strike anywhere along a pathway: a receptor tyrosine kinase that signals without any ligand bound (a stuck-on EGFR or HER2); a Ras GTPase that can no longer hydrolyse its GTP and so never switches off; a kinase like BRAF locked in the active shape; or simply too many copies of a normal growth gene. In every case the result is the same — a signal blares continuously, and the cell divides without the external permission it should require. Tellingly, oncogenes act dominantly: one over-active copy is enough, like one stuck-on switch overriding a working one. This is the mirror image of tumour-suppressor genes, the off-switches and brakes whose loss removes the restraint.
This idea matters because it ties the whole field of signaling to the disease that kills millions, and because it points straight at treatment. Since cancer cells often become dependent on the very oncogene that is driving them (a state called oncogene addiction), drugs that switch that one protein back off can be strikingly effective — kinase inhibitors against BRAF or mutant EGFR, antibodies against HER2, and the new drugs against mutant KRAS. The honest caveat is that cancers fight back: they mutate the target, or the signaling network reroutes around the blocked node, so a single switched-off oncogene is rarely a permanent cure. Still, understanding signaling as switches that can stick on has reshaped how we both explain and treat cancer.
The very first human oncogene found was a mutant RAS, isolated from a bladder-cancer cell in the early 1980s. A single base change had altered one amino acid, leaving the Ras switch unable to turn itself off. That one discovery — a normal growth gene mutated to be permanently on — became the template for understanding how signaling goes wrong in cancer.
The first oncogene was a stuck-on RAS: one base change made a normal growth switch unable to turn off.
Oncogenes (stuck-on growth switches) and tumour-suppressor genes (lost brakes) are opposite, not the same. An oncogene needs only one over-active copy to cause trouble; a tumour suppressor usually needs both copies knocked out before its restraint is gone.